Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Page 1
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.
Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. Taylor-Cousar JL, et al. Among authors: downey dg. Lancet. 2023 Sep 30;402(10408):1171-1184. doi: 10.1016/S0140-6736(23)01609-4. Epub 2023 Sep 9. Lancet. 2023. PMID: 37699418 Review.
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a new era of cystic fibrosis management has emerged-one in which scientific principles translated fr …
Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied …
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Among authors: downey dg. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability, and efficacy of tezacaftor-ivacaftor in participants aged 12 years or older with cystic fibrosis who were homozygous or heterozygous for t …
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability …
MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.
Vallières E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG. Vallières E, et al. Among authors: downey dg. ERJ Open Res. 2016 Mar 15;2(1):00064-2015. doi: 10.1183/23120541.00064-2015. eCollection 2016 Jan. ERJ Open Res. 2016. PMID: 27730175 Free PMC article.
As there is no clear consensus as to which eradication regimen is most effective, we determined the efficacy of eradication regimens used in our CF centre and long-term clinical outcome. All new MRSA positive sputum cultures (n=37) that occurred between 2000 and 2014 were …
As there is no clear consensus as to which eradication regimen is most effective, we determined the efficacy of eradication regimens used in …
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC. Downey DG, et al. J Cyst Fibros. 2005 Sep;4(3):205-7. doi: 10.1016/j.jcf.2005.05.014. J Cyst Fibros. 2005. PMID: 16019268 Free article.
MRSA may be a management dilemma for healthcare workers (HCWs) with CF. Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF. ...
MRSA may be a management dilemma for healthcare workers (HCWs) with CF. Eradication of MRSA with long-term rifampicin and fusidic aci …